Needham & Company
View Older Stories
-
Inogen Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
-
Needham & Company Upgrades Inogen, Inc (INGN) to Buy
-
Inogen Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
-
Inogen, Inc (INGN) PT Lowered to $75 at Needham & Company as COVID has Mixed Impact
-
Inogen, Inc (INGN) PT Lowered to $80 at Needham & Company, Following 8-K Filing
-
Companies with NDRs 11/20
-
Pre-Open 11/06: (FCEL) (AYR) (INGN) Higher; (PLT) (SUPN) (FLDM) Lower (more...)
-
Needham & Company Upgrades Inogen, Inc (INGN) to Buy
-
Companies with NDRs 09/10
-
Needham & Company Downgrades Inogen, Inc (INGN) to Hold
-
Needham & Company Downgrades Inogen, Inc (INGN) to Buy
-
Inogen Announces Participation in the 18th Annual Needham Healthcare Conference
-
Inogen Announces Participation in the 21st Annual Needham Growth Conference
-
Needham & Company Upgrades Inogen, Inc (INGN) to Strong Buy
-
Needham & Company Downgrades Inogen, Inc (INGN) to Buy
-
Inogen, Inc (INGN) PT Raised to $254 at Needham & Company
-
UPDATE: Needham & Company Defends Inogen (INGN) Following Short Report
-
Inogen, Inc (INGN) PT Raised to $215 at Needham & Company; 'Revenue Upside Was Breathtaking'
-
Inogen Announces Participation in 17th Annual Needham Healthcare Conference
-
Inogen, Inc (INGN) PT Raised to $150 at Needham & Company; Domestic B2B and DTC Sales Drive Results
-
Inogen Announces Participation in Upcoming J.P. Morgan Healthcare Conference & Needham Growth Conference
-
Inogen (INGN): Raising PT - Needham
-
Inogen Announces Participation in 16th Annual Needham Healthcare Conference
-
Inogen, Inc (INGN) PT Raised to $83 at Needham & Company on 4Q Revenue, EBITDA, EPS Beat; B2B Biz Up 56%
-
Inogen (INGN) G4 Product Cycle Should Improve In 2017 - Needham
-
Inogen to Participate in Upcoming Investor Conferences
-
Inogen (INGN): Raising PT to $66 - Needham
-
Inogen to Participate in Upcoming Investor Conferences
-
Needham & Company Raises Price Target on Inogen (INGN) to $64 Following 2Q Beat
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Inogen (INGN): G4 Product Cycle a Significant Catalyst - Needham & Company
-
Inogen, Inc (INGN) Product Cycle Is More Important Than EBITDA Miss - Needham & Company
-
Inogen Announces Participation in 15th Annual Needham Healthcare Conference
-
Needham & Company Raises Price Target on Inogen (INGN) to $47 Following Strong 4Q Beat and Raise
-
Needham & Company Reiterate Strong Buy on Inogen (INGN) Expecting Continued 'Beat and Raise' Story
-
Inogen Announces Participation in Upcoming Investor Conferences
-
Inogen (INGN) Raises Revenue Guidance Following 3Q Beat; Needham & Company Reiterates Strong Buy
-
Inogen (INGN) PT Raised to $51 at Needham & Company
-
Inogen (INGN) Numbers Lifted at Needham & Company on Strong Business-to-Business Growth
-
Inogen (INGN) PT Lifted to $46 at Needham & Company
-
Needham & Company Reinstates Inogen, Inc (INGN) at Strong Buy; Restatement Unlikely
-
Inogen to Participate in Upcoming Investor Conferences
-
Needham & Company Starts Inogen, Inc (INGN) at Strong Buy
-
Inogen Announces Closing of Secondary Public Offering
-
Inogen (INGN) Prices 2.1M Common Secondary Offering at $21.50/Share
-
Inogen Announces Pricing of Secondary Public Offering
-
Inogen Announces Launch of Proposed Secondary Public Offering by Selling Stockholders

